| Wagner, John |
NCT04260698: Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies |
|
|
| Active, not recruiting | 3 | 36 | US | omidubicel, NiCord | Gamida Cell ltd | Hematological Malignancies | 05/25 | 05/25 | | |
NCT02566304: Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies |
|
|
| Active, not recruiting | 2 | 35 | US | Fludarabine, Fludarabine phosphate, Fludara, Total-Body Irradiation, T Cell-Depleted Donor Lymphocyte Infusion, Cyclophosphamide, Endoxan, Cytoxan, Neosar, Procytox, Revimmune, Cycloblastin, Cytophosphane, CP, Peripheral Blood Stem Cell Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation, Tacrolimus, FK-506, Fujimycin, Prograf, Advograf, Protopic, Mycophenolate mofetil, Mycophenolic acid, MMF, CellCept, Myfortic, Laboratory Biomarker Analysis | Sidney Kimmel Cancer Center at Thomas Jefferson University | Acute Myeloid Leukemia, Acute Myeloid Leukemia in Remission, Aplastic Anemia, Chronic Myelomonocytic Leukemia, Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma, Malignant Neoplasm, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Plasma Cell Myeloma, Refractory Anemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Ring Sideroblasts, Refractory Cytopenia With Multilineage Dysplasia, Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts | 02/24 | 02/24 | | |
| Recruiting | N/A | 70 | US | | Koneksa Health, Merck Sharp & Dohme LLC, Regeneron Pharmaceuticals | Parkinson Disease | 08/25 | 09/25 | | |
NCT01451502: Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units |
|
|
| Recruiting | N/A | 250 | US | Umbilical Cord Blood (UCB) | Masonic Cancer Center, University of Minnesota | Lymphatic Diseases, Hematopoietic Malignancy | 12/25 | 12/25 | | |
| Perentesis, John P |
V2-MA-1801, NCT03826992: Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia |
|
|
| Recruiting | 1 | 21 | US | Vyxeos, cytarabine and daunorubicin liposome, CPX-351, Venetoclax, Venclexta | Children's Hospital Medical Center, Cincinnati | Leukemia | 01/25 | 01/26 | | |
| Completed | N/A | 1243 | US | | Washington University School of Medicine | Carcinoma | 06/23 | 06/23 | | |
| Recruiting | N/A | 10 | US | FLASH Radiotherapy | Varian, a Siemens Healthineers Company | Bone Metastases in the Thorax | 04/25 | 04/25 | | |
NCT01696721: Proton and Photon Consortium Registry (PPCR): A Multi Center Registry of Pediatric Patients Treated With Radiation Therapy |
|
|
| Recruiting | N/A | 5000 | US | No intervention | Massachusetts General Hospital | Pediatric Patients Treated With Radiation Therapy | 12/25 | 12/25 | | |
| Geller, Melissa A |
NCT05708924: MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer |
|
|
| Suspended | 1 | 33 | US | FT538, Enoblituzumab, RES242, MGA271 | Masonic Cancer Center, University of Minnesota, National Cancer Institute (NCI) | Cancer, Solid Tumor, Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer | 09/26 | 09/28 | | |
| Active, not recruiting | 1 | 18 | US | HCW9218, Monotherapy | Masonic Cancer Center, University of Minnesota | Solid Tumor | 01/25 | 02/26 | | |
NCT05338658: Study of PAT in Patients With Solid Tumor Cancers |
|
|
| Suspended | 1 | 21 | US | Peptide Alarm Therapy (PAT), Pembrolizumab | Masonic Cancer Center, University of Minnesota | Metastasis, Solid Tumor | 01/27 | 01/27 | | |
| Greeno, Edward W |
| Recruiting | 1 | 18 | US | Replicative Adenovirus Vector (RGDCRAdCOX2F) | Masonic Cancer Center, University of Minnesota | Adenocarcinoma of Pancreas | 10/28 | 10/29 | | |
| Tuttle, Todd M |
NCT03981705: Assessment of Complete Pathologic Response After Neoadjuvant Chemotherapy for Breast Cancer |
|
|
| Completed | N/A | 8 | US | Standard Trimodality Breast Imaging | Masonic Cancer Center, University of Minnesota | TN ER-/PR-/HER2- Breast Cancer, Triple Negative Breast Cancer, HER2-positive Breast Cancer, ERany/PRany/HER2+ Breast Cancer | 02/24 | 11/24 | | |
| Brunstein, Claudio G |
NCT06129734: Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant |
|
|
| Not yet recruiting | 1/2 | 20 | US | Venetoclax, Decitabine | Benjamin Tomlinson | Myeloid Malignancy, Acute Myeloid Leukemia | 12/25 | 12/26 | | |
NCT01962636: Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases |
|
|
| Recruiting | N/A | 200 | US | Fludarabine, Fludara, Cyclophosphamide, Cytoxan, Total Body Irradiation, Cyclosporine A, CSA, Mycophenylate mofetil, MMF, Umbilical cord blood, UCB | Masonic Cancer Center, University of Minnesota | Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myelogenous Leukemia, Plasma Cell Leukemia, Myelofibrosis, Myelodysplasia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Marginal Zone B-Cell Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Mantle-Cell Lymphoma, Prolymphocytic Leukemia, Diffuse Large B Cell Lymphoma, Lymphoblastic Lymphoma, Burkitt's Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma | 10/25 | 10/26 | | |
NCT01451502: Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units |
|
|
| Recruiting | N/A | 250 | US | Umbilical Cord Blood (UCB) | Masonic Cancer Center, University of Minnesota | Lymphatic Diseases, Hematopoietic Malignancy | 12/25 | 12/25 | | |
| Bachanova, Veronika |
| Recruiting | 3 | 1400 | Europe, Canada, Japan, US, RoW | Previously treated CAR-T patients | Novartis Pharmaceuticals, University of Pennsylvania | Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program | 02/36 | 02/36 | | |
NCT03125642: Auto Stem Cell Transplant for Lymphoma Patients |
|
|
| Recruiting | 2 | 150 | US | Etoposide, VP-16, BCNU, Carmustine, AraC, Cytarabine, cytosine arabinoside, Cytosar-U, Depocyt, Melphalan, Alkeran, Peripheral blood stem cell transplantation, PBSC, G-CSF, filgrastim, Cyclophosphamide, Cytoxan, Total Body Irradiation, TBI | Masonic Cancer Center, University of Minnesota | Non-Hodgkin Lymphoma, Hodgkin Lymphoma | 09/25 | 04/26 | | |
| Recruiting | 1/2 | 54 | US | Ruxolitinib, Jakafi, Nivolumab, Opdivo | Veronika Bachanova, Incyte Corporation, Bristol-Myers Squibb | Hodgkin Lymphoma | 07/25 | 07/27 | | |
NCT05296525: Evaluation of Safety and Efficacy of Allo GDA-201 NK Cells in Patients With Relapsed/Refractory B Cell NHL |
|
|
| Terminated | 1/2 | 13 | US | GDA-201, NAM NK | Gamida Cell ltd | Non-Hodgkin Lymphoma | 04/24 | 04/24 | | |
| Recruiting | 1/2 | 30 | US | E7777 | Masonic Cancer Center, University of Minnesota | DLBCL, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, DLBCL Arising From Follicular Lymphoma | 12/25 | 12/25 | | |
NCT05114837: Ph I/II Study of CAR19 Regulatory T Cells (CAR19-tTreg) for R/R CD19+ B-ALL |
|
|
| Withdrawn | 1/2 | 31 | US | allogeneic CAR19 regulatory T cells (CAR19-tTreg), Fludarabine, FLUDARA, Cyclophosphamide, CYTOXAN | Masonic Cancer Center, University of Minnesota | Lymphoma Leukemia | 08/28 | 08/28 | | |
NCT04555811: FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL |
|
|
| Completed | 1 | 7 | US | FT596, Rituximab, Rituxan | Masonic Cancer Center, University of Minnesota, National Cancer Institute (NCI) | NHL, Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma | 02/23 | 11/23 | | |
NCT06414278: Evaluation of Early Identification of Cognitive Side Effects of Immunotherapy |
|
|
| Recruiting | N/A | 38 | US | Non-Interventional Study | Masonic Cancer Center, University of Minnesota, National Cancer Institute (NCI) | Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm | 07/27 | 02/28 | | |
NCT03642626: MT2017-45: CAR-T Cell Therapy for Heme Malignancies |
|
|
| Active, not recruiting | N/A | 144 | US | KYMRIAH, tisagenlecleucel, YESCARTA, Fludarabine 30mg/m2 4 doses, Cyclophosphamide 500 mg/m2; 2 doses, Fludarabine 30mg/m2 3 doses, Cyclophosphamide 500 mg/m2; 3 doses, Fludarabine 25mg/m2 3 days, Cyclophosphamide 250 mg/m2; 3 days, Tecartus, Brexucabtagene Autoleucel, Abecma, Intravenous Suspension, Cyclophosphamide 900 mg/m2; 1 day, Breyanzi Injectable Product | Masonic Cancer Center, University of Minnesota | Acute Lymphoblastic Leukemia, Large B-cell Lymphoma | 02/24 | 06/28 | | |
| Knox, JoAnn |
| No trials found |
